
Amber Implants was granted Breakthrough Device Designation by FDA for its VCFix® spinal system, which aims to improve the treatment of vertebral fractures.
A first-In-human clinical trial is expected to commence in early 2022 in Europe and the U.S.
VCFix spinal system is the first solution to treat vertebral fractures that does not rely on bone cement. Through its 3D-printed perforated structure, VCFix implant aims to stimulate bone ingrowth as a more natural healing process, while providing better stability and better distribution of loads in the spine. The promise of Amber Implants is to bring an easier, more efficient and safer treatment for a broader type of fractures to the market.
Source: Amber Implants
Amber Implants was granted Breakthrough Device Designation by FDA for its VCFix® spinal system, which aims to improve the treatment of vertebral fractures.
A first-In-human clinical trial is expected to commence in early 2022 in Europe and the U.S.
VCFix spinal system is the first solution to treat vertebral fractures that does not rely on...
Amber Implants was granted Breakthrough Device Designation by FDA for its VCFix® spinal system, which aims to improve the treatment of vertebral fractures.
A first-In-human clinical trial is expected to commence in early 2022 in Europe and the U.S.
VCFix spinal system is the first solution to treat vertebral fractures that does not rely on bone cement. Through its 3D-printed perforated structure, VCFix implant aims to stimulate bone ingrowth as a more natural healing process, while providing better stability and better distribution of loads in the spine. The promise of Amber Implants is to bring an easier, more efficient and safer treatment for a broader type of fractures to the market.
Source: Amber Implants
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.